Last reviewed · How we verify
NCT06922708: MIG
Implementing Polygenic Risk Scores for Breast Cancer Prevention: a Feasibility Study
NA trial testing Integrated PRS-Enhanced Breast Cancer Risk Assessment (CanRisk model) in Breast Cancer in 100 participants. Not yet recruiting.
31 March 2026
Quick facts
| Lead sponsor | Boccia Stefania |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 100 |
| Start date | 9 June 2025 |
| Primary completion | 31 March 2026 |
| Estimated completion | 30 May 2026 |
Drugs / interventions tested
- Integrated PRS-Enhanced Breast Cancer Risk Assessment (CanRisk model)
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Boccia Stefania
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this single-arm interventional study is to learn whether integrating a polygenic risk score (PRS) into the CanRisk model can help improve breast cancer risk prediction and prevention in adult women with or without a family history of breast cancer and in women diagnosed with unilateral breast cancer. The main questions it aims to answer are: 1. Is it feasible and acceptable to add PRS testing into standard breast cancer risk assessment for healthcare professionals and patients? 2. Does PRS testing change the way individuals are categorized into low, moderate, or high-risk groups? 3. What practical barriers or facilitators do participants and healthcare staff identify when using PRS in a routine clinical setting? Participants will: * Provide a blood sample for PRS testing and for pathogenetic variants for breast cancer risk (if they have not already had genetic testing). * Complete a questionnaire on their experience and acceptance of PRS. Because this is a single-arm study, there is no separate comparison group. The study team will use the results to see how well PRS can be integrated into clinical care and whether it offers any improvements in prevention strategies for breast cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06922708
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06922708 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boccia Stefania
- Last refreshed: 3 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06922708.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing